Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease Who Are Receiving Standard of Care Treatment

NCT07178678 is registered in ClinicalTrials.gov with University of Saskatchewan as lead sponsor.

NCT NCT07178678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07178678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease Who Are Receiving Standard of Care Treatment
Lead sponsor
University of Saskatchewan
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2025
Completion date
December 31, 2030
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild alzheimer's disease, moderate alzheimer's disease